Illumina was founded in April of 1998 by David Walt, Ph.D., CW Group (Larry Bock), John Stuelpnagel, D.V.M., Anthony Czarnik, Ph.D., and Mark Chee, Ph.D. While working with CW Group, a venture capital firm, Larry and John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Headquartered in San Diego, California, Illumina completed its initial public offering in July, 2000.
Illumina began offering SNP genotyping services in 2001 and launched its first system, the Illumina BeadLab, in 2002, using GoldenGate Genotyping technology. The company acquired Solexa in 2006 and soon after launched the Genome Analyzer, the first of many Illumina sequencing systems based on the sequencing by synthesis technology.
Illumina currently offers microarray-based products and services for an expanding range of genetic analysis sequencing, including SNP genotyping, gene expression, and protein analysis. Illumina’s technologies are used by a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe.
At Illumina, we apply innovative technologies for studying genetic variation and function, making studies possible that were not even imaginable just a few years ago. These revolutionary tools for DNA, RNA, and protein analysis are enabling rapid advances in disease research, drug development, and the development of molecular tests in the clinic.



Affordable, simple, powerful


Speed & simplicity for targeted & small genome sequencing


Speed & simplicity for every day genomics


Power & efficiency for large-scale genomics

HiSeq X®​

Maximum throughput for whole genome sequencing


Illumina newest, most advanced system to date

Array Systems


High-throughput and high-quality array system
Close Menu